The new, minimally invasive procedure developed by University at Buffalo researchers utilizes delivery of an antibody that targets and thus blocks the pro-inflammatory protein called tumor necrosis factor-alpha (TNF), specifically in the brain
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from Youtube
Vimeo
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Spotify
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound
We use cookies to enhance your experience while using our website. To learn more about the cookies we use and the data we collect, please check our Privacy Settings.